Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice

Oncotarget

Volumn 7, Issue 52, 2016, Pages 87219-87231

  Lee, Su Hyung ^a   Park, Jun Won ^b   Woo, Sang Ho ^a   Go, Du Min ^a   Kwon, Hyo Jung ^c   Jang, Ja June ^a   Kim, Dae Yong ^a  

^a Seoul National University   (South Korea)

^b National Cancer Center   (South Korea)

^c Chungnam National University   (South Korea)

Author keywords

Apoptosis; C Jun; EGFR; Hepatocellular carcinoma; Osteopontin

Indexed keywords

DIETHYLNITROSAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; OSTEOPONTIN; PROTEIN C JUN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INCIDENCE; KNOCKOUT MOUSE; LIVER CANCER; LIVER CANCER CELL LINE; LIVER CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; LIVER TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DIETHYLNITROSAMINE; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOPONTIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 85007415627     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13529     Document Type: Article

References (43)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2013
2. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Seraq HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004; 127:1372-1380
3. Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, Orsini L, Kim WR, Roberts LR. Factor that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol. 2011; 9:617-623
4. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: A emerging menace. J Hepatol. 2012; 56:1384-1391
5. Ringelhan M, Protzer U. Oncogenic potential of hepatitis B virus encoded proteins. Curr Opin Virol. 2015; 14:109-115
6. Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, Tiribelli C. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinom. World J Gastroenterol. 2016; 22:1497-1512
7. Nagoshi S. Osteopontin: Versatile modulator of liver disease. Hepatol Res. 2014; 44:22-30
8. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 2007; 67:2089-2097
9. Dai N, Bao Q, Lu A, Li J. Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer. Oncology. 2007; 72:89-96
10. Kumar V, Behera R, Lohite K, Kamik S, Kundu GC. p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res. 2010; 70:10381-10391
11. Zhang R, Pan X, Huang Z, Weber GF, Zhang G. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One. 2011; 6:e23831
12. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003; 98:119-127
13. Liu X, Tian S, Liu M, Jian L, Zhao L. Wogonin inhibits the proliferation and invasion, and induces the apoptosis of HepG2 and Bel7402 HCC cells through NFkappaB/Bcl-2, EGFR and EGFR downstream ERK/AKT signaling. Int J Mol Med. 2016: doi: 10.3892/ijmm.2016.2700
14. Wang Z. Transactivation of epidermal growth factor receptor by G protein-coupled receptor: Recent progress, challange and future research. Int J Mol Sci. 2016; 17: doi:10.3390/ijms17010095
15. Nuciforo P, Radosevic-Robin N, Nq T, Scaltriti M. Quantification of HER familiy receptors in breast cancer. Breast Cancer Res. 2015; 17: doi: 10.1186/s13058-13015-10561-13058
16. Russo A, Franchina T, Ricciardi GR, Picone A, Ferraro G, Zanqhi M, Toscano G, Giordano A, Adamo V. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget. 2015; 6:26814-26825. doi: 10.18632/oncotarget.4254
17. Yiu AJ, Yiu CY. Biomarker in colorectal cancer. Anticancer Res. 2016; 36:1093-1102
18. Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver. 1999; 19:318-325
19. Cheng J, Wang W, Sun C, Li M, Wang B, Lv Y. Metaanalysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol. 2014; 48:806-814
20. Hua Z, Chen J, Sun B, Zhao G, Zhang Y, Fong Y, Jia Z, Yao L. Specific expression of osteopontin and S100A6 in hepatocellular carcinoma. Surgery. 2011; 149:783-791
21. Yoo BK, Gredler R, Chen D, Santhekadur PK, Fisher PB, Sarkar D. c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF. J Hepatol. 2011; 55:1317-1324
22. Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, Ren N, Qin LX. Lentiviralmediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008; 48:1834-1842
23. Fouad SA, Mohamed NA, Fawzy MW, Moustafa DA. Plasma osteopontin level in chronic liver disease and hepatocellular carcinoma. Hepat Mon. 2015; 15:e30753
24. Huang W, Zhu G, Huang M, Lou G, Liu Y, Wang S. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin Chim Acta. 2010; 411:675-678
25. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Mi Z, Pereira TA, Zdanowicz M, Malladi P, Chen Y, Moylan C, Jung Y, Bhattacharya SD, Teaberry V, Omenetti A, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology. 2011; 53:106-115
26. Chiche J, Rouleau M, Gounon P, Brahimi-Horn MC, Pouyssegur J, Mazure NM. Hypoxic enlarged mitochondria protect cancer cells from apoptotic stimuli. J Cell Physiol. 2010; 222:648-657
27. Lee SH, Park JW, Go DM, Kim HK, Kwon HJ, Han SU, Kim DY. Ablation of osteopontin suppresses N-methyl-N-nitrosourea and Helicobacter pylori-induced gastric cancer development in mice. Carcinogenesis. 2015; 36:1550-1560
28. Zhang H, Guo M, Chen JH, Wang Z, Du XF, Liu PX, Li WH. Osteopontin knockdown inhibits alphav, beta3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/mTOR pathway. Cell Physiol Biochem. 2014; 33:991-1002
29. Zhang A, Liu Y, Shen Y, Xu Y, Li X. Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells. Med Oncol. 2010; 27:1179-1184
30. Hsieh YH, Juliana MM, Hicks PH, Feng G, Elmets C, Liaw L, Chang PL. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res. 2006; 66:7119-7127
31. Matusan-Ilijas K, Damante G, Fabbro D, Dordevic G, Hadzisejdic I, Grahovac M, Maric I, Spanjol J, Grahovac B, Jonjic N, Lucin K. Osteopontin expression correlates with nuclear factor-kappaB activation and apoptosis downregulation in clear cell renal cell carcinoma. Pathol Res Pract. 2011; 207:104-110
32. Tilli TM, Mello KD, Ferreira LB, Matos AR, Accioly MT, Faria PA, Bellahcene A, Castronovo V, Gimba ER. Both osteopontin-c, osteopontin-b splicing isoforms exert protumorigenic roles in prostate cancer cells. Prostate. 2012; 72:1688-1699
33. Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J, Li K, Tong X, Dai J, Yao S, Wu M, Guo Y. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology. 2008; 135:956-968
34. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 2001; 276:46024-46030
35. Xu YP, Lin G, Sun XJ, Yan MH, Zhang G, Hu JL, Sun WY, Yu JM. c-Met as a molecular marker for esophageal squamous cell carcinoma and its association with clinical outcome. J Cancer. 2016; 7:587-594
36. Rao CV, Janakiram NB, Madka V, Devarkonda V, Brewer M, Biddick L, Lightfoot S, Steele VE, Mohammed A. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget. 2015; 6:33290-33305. doi: 10.18632/oncotarget.5396
37. Jin W, Chen BB, Li JY, Zhu H, Huang M, Gu SM, Wang QQ, Chen JY, Yu S, Wu J, Shao ZM. TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Mol Cell Biol. 2012; 32:50-63
38. Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D, Habib AA. Ligand-independent EGFR signaling. Cancer Res. 2015; 75:3436-3441
39. Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, Cavalloni G, Torchio B, Mosso L, Chiorino G, Aglietta M. Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer. 2011; 11:31
40. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinibsensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science. 2004; 305:1163-1167
41. Zenz R, Scheuch H, Martin P, Frank C, Eferl R, Kenner L, Sibilia M, Wagner EF. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev cell. 2003; 4:879-889
42. Tsai WC, Tsai WC, Lee HS, Jin JS, Gao HW, Chao TK, Chen A, Nieh S, Chan DC, Chang FN, Lin CK. Association between osteopontin and EGFR expression with clinicopathological parameters in hepatocellular carcinoma. Chin J Physiol. 2012; 55:412-420
43. Fan X, He C, Jing W, Zhou X, Chen R, Cao L, Zhu M, Jia R, Wang H, Guo Y, Zhao J. Intracellular Osteopontin inhibits toll-like receptor signaling and impedes liver carcinogenesis. Cancer Res. 2015; 75:86-97